<?xml version="1.0" encoding="UTF-8"?>
<p>This investigation included six studies (the Framingham Heart Study (FHS), the Estonian Biobank (EGCUT), the Rotterdam Study (RS) [
 <xref rid="pgen.1005035.ref008" ref-type="bibr">8</xref>], the InCHIANTI Study, the Cooperative Health Research in the Region of Augsburg (KORA F4) Study [
 <xref rid="pgen.1005035.ref009" ref-type="bibr">9</xref>], and the Study of Health in Pomerania (SHIP-TREND) [
 <xref rid="pgen.1005035.ref010" ref-type="bibr">10</xref>], each of which conducted genome-wide genotyping, mRNA expression profiling, and had extensive BP phenotype data. Each of the six studies followed the recommendations of the Declaration of Helsinki. The FHS: Systems Approach to Biomarker Research (SABRe) in cardiovascular disease is approved under the Boston University Medical Centerâ€™s protocol H-27984. Ethical approval of EGCUT was granted by the Research Ethics Committee of the University of Tartu (UT REC). Ethical approval of the InCHIANTI study was granted by the Instituto Nazionale Riposo e Cura Anziani institutional review board in Italy. Ethical approval of RS was granted by the medical ethics committee of the Erasmus Medical Center. The study protocol of SHIP-TREND was approved by the medical ethics committee of the University of Greifswald. KORA F4 is a population-based survey in the region of Augsburg in Southern Germany which was performed between 2006 and 2008. KORA F4 was approved by the local ethical committees. Informed consent was obtained from each study participant.
</p>
